As people age, systemic inflammation can inflict degenerative effects throughout the body. A primary cause of this destructive cascade is the production of cell-signaling chemicals known as inflammatory cytokines. Along with these dangerous cytokines, imbalances of hormone-like messengers called prostaglandins and leukotrienes also contribute to inflammatory processes.

The typical American diet is loaded with foods that contain arachidonic acid (like egg yolk, red meat, poultry, and dairy products) or stimulate the production of excess arachidonic acid in the body (foods rich in high-glycemic carbohydrates, saturated fats, and omega-6 fatty acids).

Scientific studies show that excess arachidonic acid increases levels of the 5-lipoxy-genase (5-LOX) enzyme, which can induce undesirable effects in cells. This may result in the excess accumulation of leukotriene B4, a pro-inflammatory compound that attacks the joints, the arterial wall, and other tissues.

In India, extracts from the Boswellia plant have been used for centuries as fluid-balancing agents. Human studies have confirmed that a specific Boswellia extract known as AKBA (3-O-acetyl-11-keto-ß-boswellic acid) selectively inhibits 5-LOX. Unlike other boswellic acids that only partially inhibit 5-LOX, AKBA binds directly to 5-LOX, effectively suppressing its pro-inflammatory activity. A recent study indicated that 5-LOXIN® may exert its beneficial effects by controlling inflammatory responses through reducing pro-inflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage. A 90-day, double-blind, randomized, placebo-controlled study demonstrated 5-LOXIN® reduces joint discomfort and improves physical functioning significantly in human subjects.

5-LOXIN is a registered trademark of P.L. Thomas & Co., Inc. U.S. patents pending.